Readthrough drugs are a class of therapeutics designed to target genetic mutations that lead to premature stop codons, also known as nonsense mutations. These mutations cause the premature termination of protein synthesis, leading to truncated and often non-functional proteins. In the context of cancer, such mutations can affect tumor suppressor genes, compromising their ability to regulate cell growth and division properly.
